Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
Randomized, open-label, multicenter study to compare the efficacy and safety of zanubrutinib
plus eltrombopag compared to eltrombopag monotherapy for the first-line treatment of adults
with chronic immune thrombocytopenia (ITP).
Phase:
Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
Beijing Aerospace General Hospital Beijing Hospital Beijing Tongren Hospital Qilu Hospital of Shandong University The Sixth Medical Center of PLA General Hospital